Logo CICANCER

Cell-of-origin of prostate cancer and clinical heterogeneity

Cell-of-origin of prostate cancer and clinical heterogeneity

Esther Baena Chaparro

Cancer Research UK Manchester Institute [Manchester, UK]

Date: 16/05/2019
Time: 12:30:00
Salón de actos del Centro de Investigación del Cáncer
Sandra Blanco

Personalized treatment for prostate cancer remains a challenge because there are no clear molecular subtypes to guide patient response. Imaging, PSA levels and pathological assessment of biopsies through the Gleason grading system remain the gold standard for diagnosis and risk stratification. Moreover, most genomic campaigns analysed single biopsies with reduce analysis of their cellular landscape, which limit the value of this analysis in what is known to be a m